ICIs are monoclonal antibodies (mAbs) targeting checkpoint proteins expressed by immune cells or tumour cells, such as PD-1, programmed cell death protein-ligand 1 (PD-L1) and CTLA-4. This evidence concerns the gene CTLA4 and neoplasm.